To date, there is a limited amount of literature that describes the features of the microbial composition of plaque in patients with a confirmed diagnosis of SARS-CoV-2. Therefore, this topic is relevant today. Thus, the purpose of this study was to study the characteristics of the microbial composition of dental plaque in patients with a laboratory-confirmed diagnosis of SARS-CoV-2 of mild to moderate severity, with the presence of concomitant oral coinfection or its absence. Knowledge of the features of the microbial composition of dental plaque in patients with Sars-CoV-2, as well as timely treatment of inflammatory diseases of the oral cavity will constitute an important stage in the algorithm of specialized therapy. The work carried out a comprehensive assessment of the features of the microbial composition of dental plaque in patients with a confirmed diagnosis of SARS-CoV-2. The conclusions are based on the results of a clinical study, which compared the characteristics of the microbial composition of dental plaque in 90 patients aged 20 to 65 years with mild to moderate Sars-CoV-2 with oral coinfection and 15 aged 20 to 65 years with mild to moderate Sars-CoV-2 with no coinfection. Results. In the course of the study, the following results were obtained. Patients with + coinfection had a severe course of the disease, transfer to the NIVL was more often required; the duration of hospitalization increased; longer treatment and long-term rehabilitation was required, aimed at normalizing indicators and normalizing the microflora. Based on this, it can be assumed that the presence of oral coinfection affects the severity of the condition and the course of Sars-CoV-2. This means that the risk of coinfection, secondary infection should be taken into account. And, finally, knowledge of the mechanisms of interaction of viruses, fungi and bacteria gives hope for the creation of drugs that will effectively resist even such combined attacks. Conclusions. The available evidence suggests that the oral cavity may be an active focus of infection and an important reservoir of SARS-CoV-2.

At the end of 2019, an outbreak of a new coronavirus infection occurred in the People's Republic of China with an epicenter in the city of Wuhan [26]. The causative agent was given the temporary name 2019-nCoV. The World Health Organization officially named the infection-COVID-19 on February 11, 2020. The official name of the causative agent of infection SARS-CoV-2, was assigned by the international committee on the taxonomy of viruses [22]. A number of authors have established that the main role is played by receptors of angiotensin converting enzyme 2 (ACE2) in the penetration of the virus into target cells [19]. It is known that the transmission of SARS-CoV-2 occurs more often by airborne droplets during close contact with infected patients [15], as well as through direct contact with infected people and infected objects [17, 18, 20]. For healthcare professionals, SARS-CoV-2 has set tasks related to the rapid diagnosis and provision of medical care to patients. Currently, information on the clinical features, epidemiology, prevention and treatment of this disease is limited [13, 14]. To date, there is a limited amount of literature describing the dental status in patients diagnosed with SARS-CoV-2. Thus, the purpose of this study was to study the state of oral mucosa and substantiate its changes in patients with a laboratory-confirmed diagnosis of SARS-CoV-2 of mild to moderate severity, with or without concomitant oral coinfection. On the other hand, knowledge of the peculiarities of the dental status of Sars-CoV-2 patients and timely rational treatment of diseases of the oral cavity should constitute an important stage in the algorithm for their specialized therapy [2]. The work carried out a comprehensive assessment of the state of the oral cavity and the need for dental treatment in patients with Sars-CoV-2. The conclusions are based on the results of a simple observational clinical study, in which a comparative assessment of dental status indicators was carried out in 40 patients with Sars-CoV-2 and 20 somatically healthy individuals of the same sex and age.

261,435,768 COVID-19 infections were detected worldwide, of them 5,207,634 deaths were registered. Identifying markers of the patient severity early in the course of the disease can facilitate the assessment of the risk of adverse outcome.The objective: To compare values of laboratory parameters and their changes during treatment of patients with a complicated course of COVID-19 infection.Subjects and Methods. 56 patients were included in the study, all of them were hospitalized to COVID Hospital of the Clinic of Bashkir State Medical University, Russian Ministry of Health, from September 30, 2021 to November 15, 2021, and their complicated course of the disease necessitated transfer to the intensive care unit (ICU). The laboratory evaluation included the following: a general blood and urine counts, blood chemistry including urea and creatinine, liver transaminases, and blood coagulogram (prothrombin time (PTT), prothrombin index (PTI), thrombin time, fibrinogen, and blood clotting time).Results. In the group of patients with a fatal outcome on the day of transfer to ICU, lymphocytopenia, eosinopenia, elevated values of creatinine, total bilirubin, transaminases, C-reactive protein, D-dimer, and ferritin were noted. Also on this day, microscopic hematuria, proteinuria and cylindruria were detected in the urine tests of most patients in this group during treatment.Conclusion. Critical deviations in the results of hematological and biochemical tests were revealed. Particular attention should be paid to such parameters as the level of erythrocytes, lymphocytes, eosinophils, glucose, urea, creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatine kinase, C-reactive protein, D-dimer, and ferritin.

To date, there is a limited amount of literature that describes the use of oral therapeutic and prophylactic drugs in patients with a confirmed diagnosis of SARS-CoV-2. Therefore, this topic is relevant. Thus, the purpose of this study was to study the effectiveness of the use of therapeutic and prophylactic agents in patients with a laboratory-confirmed diagnosis of mild to moderate SARS-CoV-2, with or without concomitant oral co-infection. The data of the conducted study will constitute an important stage in the algorithm of specialized therapy. Materials and methods. A comparative analysis of the use of therapeutic and prophylactic agents for the oral cavity in patients with a confirmed diagnosis of SARS-CoV-2 was carried out. The conclusions are based on the results of a clinical study that compared the effectiveness of the use of therapeutic and prophylactic agents in 90 patients aged 20 to 87 years with mild to moderate Sars-CoV-2 with oral co-infection and 15 patients aged from 20 to 87 years of age with mild to moderate Sars-CoV-2 without coinfection. Results. During the study, the following results were obtained. The most effective drug was a solution of aqueous chlorhexidine 0.5%, but there was a side effect in the form of xerostomia. The Miramistin solution also had high efficiency, and the lowest efficiency was observed when using the Rotokan solution. Conclusions. The data of the conducted study will constitute an important stage in the algorithm of specialized therapy.

To date, there is a limited amount of literature that describes the dental quality of life measures on the OHIP-49-RU scale in patients with a confirmed diagnosis of SARS-CoV-2. Therefore, this topic is relevant. Thus, the aim of this study was to study the dental quality of life indicators according to the OHIP-49-RU scale in patients with a confirmed diagnosis of SARS-CoV-2 of moderate severity, with concomitant oral co-infection. Materials and methods: a comparative analysis of quality of life indicators according to the OHIP-49-RU scale was carried out in patients with a confirmed diagnosis of SARS-CoV-2. The conclusions are drawn based on the results of the survey, in which a comparative assessment of quality of life indicators on the OHIP-49-RU scale was carried out in 90 patients aged 45 to 60 years with moderate Sars-CoV-2 with oral co-infection. Results. During the study, the following results were obtained. An analysis of the effectiveness of the use of therapeutic and prophylactic agents in patients with SARS-CoV-2 showed that the use of a 0.05% solution of chlorhexidine bigluconate in patients with Sars-CoV-2 with concomitant oral co-infection has a more pronounced antimicrobial effect, which helps to reduce the intensity of inflammatory process in the oral mucosa and periodontal tissues, improving the quality of life than with the use of Miramistin and Rotokan. Findings. The data of the conducted study will constitute an important stage for improving the quality of life in patients with SARS-CoV-2.